OXFORD UNIVERSITY INNOVATION CLICK-TO-LICENCE PORTAL

Human-Based In Silico Prediction of Drug induced Cardiac Effects 

Virtual Assay is a framework that allows pharmaceutical companies to run in silico drug trials in populations of human cardiac cell models to predict drug safety and efficacy. Version 4 brings electrophysiology and contractility together in a single, validated, human-based mechanistic framework — enabling early, quantitative prediction of both electrical and mechanical cardiac risk.  

Virtual Assay is also closely aligned with the FDA’s 2025 “Roadmap to Reducing Animal Testing in Preclinical Safety Studies”, as well as the UK Government’s 2025 strategy “Replacing animals in science: a strategy to support the development, validation and uptake of alternative methods”. By providing human-relevant science in silico, Virtual Assay can support companies’ transitions away from animal testing, in line with the recommendations from the FDA and other regulatory agencies.

Virtual Assay Version 4 is not intended to replace experimental science – but by combining human-specific mechanistic modelling, contractility and electrophysiology integration, population variability and quantitative validation, Virtual Assay enables smarter experimentation, earlier de-risking, and more informed portfolio decisions.

• Simultaneous prediction of proarrhythmic and inotropic risk
• Quantitatively validated contractility prediction (86–95% agreement benchmarks)
• Reduced reliance on ex vivo animal testing through human-based modelling
• Replacement pathway for animal experiments
• Human-specific modelling eliminating species translation issues
• Mechanistic, auditable drug–channel–tension traceability
• Population-level risk stratification
• High-throughput concentration-response simulation

Price list for Virtual Assay 4

If you are an academic wanting a non-commercial licence for carrying out research using Virtual Assay v4, please email enquiries@innovation.ox.ac.uk